- Home
- VANI vs IMUX Comparison
VANI vs IMUX Comparison
Compare VANI & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VANI | IMUX |
|---|---|---|
| Founded | 1998 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.9M | 85.8M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | VANI | IMUX |
|---|---|---|
| Price | $1.28 | $0.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $4.00 | ★ $6.00 |
| AVG Volume (30 Days) | 178.0K | ★ 1.7M |
| Earning Date | 11-13-2025 | 02-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.91 | $0.51 |
| 52 Week High | $1.92 | $1.39 |
Technical Indicators
Market Signals| Indicator | VANI | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 43.95 | 48.52 |
| Support Level | $1.25 | $0.64 |
| Resistance Level | $1.35 | $0.71 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 56.21 | 57.76 |
Price Performance
Historical ComparisonAbout VANI Vivani Medical Inc. (DE)
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.